



தமில்நாடு TAMILNADU
MADRAS DIABETES RESEARCH
FOUNDATION
CHENNAI - 600086.

- 9 JAN 2026

ET 387147

S. Kanakaraj
S KANAKARAJ
Licence No: 3017/D2/1995
No. 662, Anna Salai, Thousand Lights,
CHENNAI - 600 006. Cell: 99414 17940

**Collaboration Agreement on the study on mHealth interventions for
Gestational Diabetes Mellitus**

This Collaboration Agreement (“Agreement”) is made and entered into on this 9th day of January 2026, by and between

Madras Diabetes Research Foundation having its Registered office at: No: 4, Conran Smith Road, Gopalapuram, Chennai- 600086. (hereinafter referred to as “MDRF”, which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns)

And

Centre of excellence for Social Determinants of Health (CoESD0H) BLDE (Deemed To Be University), having its Registered office at: Bangaramma Sajjan Campus, B.M.Patil Road (Sholapur Road), Vijayapura – 586103. (hereinafter referred to as “BLDE”, which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns)

[Signature]



[Signature]



MDRF and BLDE shall hereinafter be individually referred to as a "Party" and collectively as the "Parties"

WHEREAS:

- A. MDRF is engaged in scientific and clinical research in the field of diabetes and related disorders, including advanced genomic and molecular studies.
- B. **BLDE (DU) Shri B M Patil Medical College Hospital & Research Centre, Vijayapura**, operational since September 1986, offers Undergraduate, Postgraduate, Super-Specialty, and Doctoral programs and has established itself as a centre of excellence in medical education, clinical services, and research. With a globally placed alumni network, a highly qualified and research-oriented faculty, and a proactive, student-centric administration, the institution provides a strong foundation for academic and research collaboration. The Medical College and its affiliated Teaching Hospital are co-located on a 54-acre campus in the heart of the city, facilitating integrated teaching, training, and patient care. The campus infrastructure, which includes academic departments, a central library, and residential facilities housed in dedicated blocks, is well suited to support joint academic programs, clinical training, faculty exchange, and collaborative research initiatives under this Memorandum of Understanding.
- C. The Parties wish to collaborate for the conduct of the study titled "**Effect of mHealth interventions for lifestyle modification on Gestational Diabetes Mellitus and on Maternal and Foetal Outcomes: An Experimental Study.**"
- D. This agreement shall be deemed to be commenced on and from 8th day of January 2026.

NOW THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

1. Purpose and Scope of the Agreement:

- Joint planning and execution of the research study on mHealth interventions for gestational diabetes and related outcomes.
- Development and integration of digital health tools, including the use of the WINGS Module, with technical support from MDRF and project leadership from BLDE.
- Shared responsibilities for data collection, analysis, and interpretation, with both parties ensuring secure data management and confidentiality.
- Mutual agreement on publications, presentations, and any intellectual property generated through the collaboration.



- Restrictions on sharing project-related information with third parties without written consent from both parties.
- Adherence to all required ethical approvals and institutional guidelines for the conduct of the research.

2. Objectives of the Agreement:

2.1. Primary:

- 2.1.1. To evaluate the effect of mHealth interventions for structured modifications of lifestyle risk factors in reducing blood glucose levels among pregnant women with Gestational Diabetes Mellitus (GDM).
- 2.1.2. To explore and compare the impact of these interventions on maternal health and foetal outcomes among both GDM and Non GDM mothers.

2.2. Secondary:

- 2.2.1. To assess the compliance rate of mHealth interventions for structured lifestyle modifications in GDM and note the barriers and facilitators using mhealth interventions

3. Responsibilities of BLDE (DU):

The Research Project at BLDE (Deemed to be University), India will be conducted under the leadership of Professor Dr. Shailaja S. Patil (PI) and in charge of CoESDoH, and Dr. Roopa Mendagudli (Co-PI) PhD Scholar, Assistant professor GIIMS, Kalaburgi. Both PI and Co-PI will be responsible for overall conduct of the project, implementation and outcome including conference presentations and publications. BLDE will retain ownership of all raw data collected during the study. However, the analysed datasets derived from this data will be jointly accessible to both BLDE and MDRF for research, publication, and further analysis purposes. The developed mHealth intervention app will remain the property of BLDE investigators. The data collected and developed for the mHealth intervention (APP) will remain with the investigators at BLDE. However, joint publications and presentations can only be made with mutual consent.

4. Responsibilities of Madras Diabetes Research Foundation:

Faculty/Researcher from MDRF will provide technical support and guidance for the development and implementation of the project, including any necessary training to ensure its successful completion. MDRF will grant permission for the use of the "WINGS Module for GDM mothers" and support its integration into the digital platform or "APP" developed by the investigators.






5. Duration and Termination of the Agreement:

- 5.1. **Duration:** It shall remain in effect for an initial period of two (2) years from the date of execution and may be renewed for additional periods by mutual written agreement of both parties. This Agreement is effective from the date of signatures by the authorised representatives of Madras Diabetes Research Foundation and the Centre of Excellence for Social Determinants of Health, BLDE (Deemed to be University).
- 5.2. **Amendment:** This Agreement constitutes the entire understanding between the Parties and supersedes all prior discussions or communications regarding the subject matter herein. No modification or amendment shall be valid unless executed in writing and signed by authorized representatives of both Parties.
- 5.3. **Termination:** This Agreement may be terminated by either Party by providing written notice of termination to the other Party at least one (1) month prior to the desired termination date. Before issuing a notice of termination, the Parties shall make reasonable efforts to resolve any disputes or issues amicably through discussion or mediation.
- 5.4. **Survival of Rights and Obligations:** The termination of this Agreement shall not affect the rights or obligations of either party regarding any binding offer, intellectual property, confidentiality, or firm obligation approved and agreed to by either party prior to the termination date. Both Parties shall continue to honour confidentiality, data access and publication rights as agreed herein for a period of five (5) years after termination.

6. Confidentiality:

During the period of collaborative study, and for five (5) years thereafter, neither party shall share any confidential information or data generated under this MOU with any third party without prior written consent of the other party. Data generated through such collaborative research will be published in scientific journals jointly. Confidential information shall be deemed to include information which was described as such at the point of disclosure and was marked as "confidential".

The confidentiality obligations in this clause shall not apply where the confidential or proprietary information:

- a) has become public knowledge, other than through an unauthorised disclosure by the Parties;
- b) was already known to the Party, prior to disclosure by the other Party;



- c) was disclosed to the Party by a third party, whom to the receiving party's knowledge, was not under any obligation of confidence to the other Party;
- d) was released from confidential status by written authorisation of the other Party;
or
- e) is required to be disclosed by law or by requirement of a regulatory body or court order.

7. Intellectual Property Rights (IPR):

- 7.1. All background IP of each Party shall remain the sole and exclusive property of the respective Party.
- 7.2. Any intellectual property generated directly or indirectly by collaborative research or activities shall be subject to a separate written agreement between the Parties.

8. Publication:

Data generated through such collaborative research will be published in scientific journals jointly, with both parties reviewing and approving any manuscripts or presentations at least thirty (30) days prior to submission. Neither party may include the other party's confidential information in publications without first securing written consent from the information owner.

9. Force Majeure:

Neither Party shall be liable for any failure or delay in performing its obligations under this Agreement if such failure or delay is caused by an event beyond its reasonable control, including but not limited to natural disasters, wars, riots, epidemics, or government restrictions. The affected Party shall notify the other in writing without undue delay of the occurrence and expected impact of such event, use reasonable efforts to mitigate its effects, and resume performance as soon as practicable. If the Force Majeure event continues for more than sixty (60) days, the Parties shall in good faith, determine the future course of action




10. Dispute Resolution, Governing Law and Jurisdiction:

- 10.1. The Agreement shall be governed by and construed in accordance with the laws of India. Any dispute, controversy or claim arising out of this Agreement, including its interpretation, performance or termination, shall be subject to the exclusive jurisdiction of the courts in Chennai, Tamil Nadu, India, and proceedings will be conducted in English.
- 10.2. Any disputes, controversies, or claims arising from or in connection with this Agreement shall first be resolved amicably between the Parties through mutual discussion. If any dispute cannot be resolved amicably within thirty (30) days, it shall be referred to Arbitration in Chennai in accordance with the Arbitration and Conciliation Act, 1996. The Arbitration shall be conducted by a sole arbitrator jointly appointed by the Parties and the proceedings shall be conducted in English. The Arbitral Award shall be final and binding.

11. Miscellaneous:

- 11.1. **Financial Liability:** There shall not be any financial liability among the parties. The party visiting the other institute shall bear their own travel and incidental expenses. The host institution shall provide reasonable accommodation and local hospitality.
- 11.2. **Ethical Compliance:** All research activities under this Agreement shall comply with applicable institutional, national, and international ethical guidelines. Necessary approvals from ethics committees must be obtained prior to commencement of research involving human participants. Costs for such review will be determined by respective IRB/IEC as they are independent.



IN WITNESS WHEREOF, THE PARTIES HERETO HAVE CAUSED THIS AGREEMENT TO BE DULY EXECUTED AND DELIVERED BY THEIR DULY AUTHORISED REPRESENTATIVES AS OF THE DAY AND YEAR HEREINABOVE WRITTEN.

SIGNED FOR AND ON BEHALF OF:

Madras Diabetes Research Foundation

BLDE (Deemed to be University),



Name: Dr. Ranjit Mohan Anjana

Designation: President



Name: Dr. Shailaja. S. Patil

Designation: Professor Community Medicine COE for Social Determinants of Health

Centre of Excellence for Social Determinants of Health
BLDE (DU) Vijayapura.

Signature Witness

(Name & address)

Signature Witness

(Name & address)

1.

Ranji
SUSILA G.
Gopalapuram
Chennai - 86

1.

Chandru
Dr. Chandru Doddikar
Deputy Director, R&D Cell.

2.

Pradeep
DEVEKA P R
Gopalapuram
Chennai - 86.

2.

Dr
M. M. PATIL
Director RDC, BLDE DU
Vijayapura

